Wake Forest University

Smithkline Beecham Corporation

Johns Hopkins University

Floyd H Chilton

James David Winkler

Lisa A Marshall

Ruth Judik Mayer

James S Dixon

Ralph F Hall

Leslie B Poole

Timothy D Howard

Derek Parsonage

Susan Sergeant

Fan Lu

Raplh F Hall

The present invention relates to recombinant vectors, modified microorganisms, and methods for omega-3 polyunsaturated fatty acid production.

Modified microorganisms as sustainable sources of omega-3 polyunsaturated fatty acid production

Compositions and methods for identifying and treating patients having altered capacity for LC-PUFA production are disclosed.

Compositions and methods for epigenetic regulation of long chain polyunsaturated fatty acid production

The present invention provides compositions, methods, and kits comprising PUFAs produced by microalgae, in particular omega-3 and/or omega-6 fatty acids produced by members of the genus, in particular. The invention also provides compositions, methods, and kits comprising the PUFAs for the prophylactic and/or therapeutic treatment of a disease or condition, in particular a cardiovascular and/or inflammatory disease or condition.

Compositions, methods, and kits for polyunsaturated fatty acids from microalgae

The present invention provides methods of treating an inflammatory disorder, or a disorder having an inflammatory component, in a mammalian subject in need of such treatment by administering to said subject an effective amount of a composition in unit dosage form for delivery of a daily dose of said composition, said composition consisting essentially of: (i) an effective amount of &#x3b3;-linolenic acid (GLA) for increasing dihomogammalinolenic acid (DGLA) levels in the inflammatory cells of said mammalian subject, thereby inhibiting the metabolism of arachidonic acid; (ii) an effective amount of a &#x394;desaturase inhibitor for inhibiting accumulation of arachidonic acid in the serum of said mammalian subject; and, optionally, (iii) an effective amount of a competitive inhibitor of arachidonic acid metabolism. Preferred formulations may be in the form of a good tasting, preferably milk or fruit based drink, or a dried powder. The compositions reduce inflammation and inhibit the increase in serum arachidonic acid associated with gamma-linolenic acid.

Methods and compositions for the treatment of asthma

Compositions for the treatment of symptoms of inflammatory disorders may include gamma-linolenic acid or dihomogammalinolenic acid, an inhibitor of &#x394;desaturase, and optionally stearidonic acid or &#x3c9;-3 arachidonic acid. Preferred formulations may be in the form of a good tasting, preferably milk or fruit based drink, or a dried powder. Compositions reduce inflammation and inhibit increase in serum arachidonic acid associated with gamma-linolenic acid.

Dietary control of arachidonic acid metabolism

The present invention is directed towards the control of inflammation. More specifically there are provided herein dietary fatty acid regimens that may be used to inhibit the increase of serum arachidonic acid when GLA is provided as a dietary supplement.

Anti-inflammatory compounds

This invention relates to the novel pharmaceutical compositions of Formulas (I) and (II) each of which comprises a compound of Formula (I) or (II) and a pharmaceutically acceptable diluent or carrier. This invention also relates to a method of treating or reducing inflammation in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound or composition of Formula (I) or (II).

Growing community of inventors

Pilot Mountain, NC, United States of America

Floyd H Chilton